ArticleJVS-vascular insights2025
Platelet activation in patients with peripheral artery disease from 43 sites: Assessment of samples transported by overnight mail.
Article in JVS-vascular insights, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Background: Platelet activation plays a key role in peripheral artery disease, but the relevant platelet activation mechanisms in chronic limb-threatening ischemia remain unclear. Moreover, multicenter studies of in vivo platelet activation remain difficult owing to methodological limitations. We report the feasibility of a novel method to measure in vivo platelet activation using samples sent via overnight mail. We hypothesized that platelet function would be measured reliably after overnight transport. Methods: Peripheral venous blood was drawn from 190 participants with severe peripheral artery disease at 43 sites in BEST-CLI (Best Endovascular vs Best Surgical Therapy in Patients with Chronic Limb Ischemia) and shipped by Federal Express cold pack from study site locations within the continental United States to Vanderbilt University Medical Center from July 2017 to November 2019. Fifty-six volunteers with and without diabetes were recruited locally as time- and age-matched control subjects. Samples were collected using a platelet activation inhibitor. Markers of platelet activation, thromboxane B2, dilysyl-malondialdehyde (MDA), p-selectin, WEDE 15, and SPAN 12 were measured using liquid chromatography with tandem mass spectrometry and flow cytometry. The primary objective was to report baseline markers of platelet activation from samples sent by overnight mail compared with an age-matched population recruited locally without known atherosclerosis. Results: Compared with control subjects, patients from BEST-CLI were more likely to be male (72.6% vs 51.8%; Conclusions: Measurement of platelet activation after sample shipment on cold pack is feasible and yields reliable results that correspond with locally obtained clinical values.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.